Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 9Terminated 5Withdrawn 2Unknown 2Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma, Large B-Cell, Diffuse 32Lymphoma, Follicular 25Lymphoma, Mantle-Cell 23Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell 16Lymphoma, B-Cell, Marginal Zone 13Neoplasms 8Recurrence 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Burkitt Lymphoma 5Neoplasm, Residual 3Lymphoproliferative Disorders 3Leukemia, Hairy Cell 3Hematologic Diseases 3Myelodysplastic Syndromes 2Lymphoma, AIDS-Related 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Blast Crisis 2Sarcoma, Myeloid 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neuritis 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myeloid Diseases 1

Interventions

Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Melphalan 2Etoposide 2Cyclophosphamide 2Busulfan 2venetoclax 1selinexor 1fludarabine phosphate 1fludarabine 1Triamcinolone 1Sirolimus 1Rituximab 1Receptors, Chimeric Antigen 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Cyclosporine 1Carboplatin 1Automobiles 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Dendritic Cell Sarcoma, Interdigitating × Rituximab × Clear all
NCT03064867 2022-11-16

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Case Comprehensive Cancer Center

Phase 1/2 Active not recruiting
65 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡